
What happened
Microbot Medical Inc. (NASDAQ: MBOT) said third-quarter revenue fell to $72,000 from $241,000 in the second quarter. Use of its LIBERTY Endovascular Robotic System rose 44% over the same span, and about $62 million in cash backs the commercial rollout.
The company reported the results on Nov. 16. It filed its Form 10-Q for the quarter ended Sept. 30 and furnished a press release in an 8-K. It said its cash, cash equivalents and marketable securities are enough to keep executing its commercial strategy in the U.S. and abroad.
Management blamed the revenue drop on the timing of customer re-orders and on third-quarter seasonality, when summer activity is lower. It also pointed to hospital Value Analysis Committee reviews, which take about 4 to 6 months. The full market release began about six months ago, and several potential new accounts are still in review.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Q3 2026 revenue (Q2 2026: $241,000) | $72,000 | -70.1% | Calculated from SEC 8-K Exhibit 99.1 |
| Cash, cash equivalents and marketable securities at Sept. 30, 2026 | about $62 million | SEC 8-K Exhibit 99.1 | |
| LIBERTY procedure utilization, Q3 versus Q2 | +44% | +44% | SEC 8-K Exhibit 99.1 |
| Customer accounts at quarter end (Q2: 10) | 12 | +2 accounts | Calculated from SEC 8-K Exhibit 99.1 |
| Cost of goods sold, Q3 versus Q2 | +24% | +24% | SEC 8-K Exhibit 99.1 |
Read more: Microbot Medical (MBOT) company research
Customers and territories
The customer base grew even as revenue shrank. Microbot ended the quarter with 12 accounts, up from 10 at the end of the second quarter. The company said 100% of current customers who used up their initial inventory have reordered multiple systems.
New accounts include an academic center in North Carolina, the company's second health system in that state. They also include its first West Coast customer, in California, which is also its first Office-Based Lab customer. Customers have used LIBERTY in prostatic, Y-90, genicular and uterine artery procedures.
Microbot added two sales territories in the quarter, bringing the total to ten. It plans to reach 12 by the end of 2026.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
Why it matters
OptimistFi's calculation puts the sequential revenue decline at 70.1%. Procedure use and account count moved the other way. Adoption inside existing hospitals is still building, while revenue swung with re-order timing and hospital approvals.
OptimistFi has argued that MBOT works only as a balance-sheet-backed option that needs regulatory or commercial proof before financing pressure returns. The cash balance supports the first part. The quarter's revenue shows commercial proof is still early.
The company's own risk wording points the same way. It lists the length and outcome of hospital purchasing processes, the resulting swings in quarterly revenue, its need for more capital and its cash resources.
Where gross margin stands
Gross margin was negative, which the company said it expected. Cost of goods sold rose 24% from the second quarter, largely because of an inventory write-down. It was recognized when inventory was measured at the lower of cost and net realizable value. The write-down is a one-time item, not a sign of higher ongoing production costs.
Under first-in, first-out accounting, the cost of systems sold also mainly reflected units built earlier at higher production costs. The company said the manufacturing cost per unit produced in the quarter kept declining from prior quarters.
Management believes its cost reductions and a planned second manufacturing line could enable positive gross margin during 2027. The line must be completed as planned, so the 2027 target rests on work that has not yet happened.
What's next
Microbot expects initial orders under its Israel distribution agreement with Medtechnica Ltd. in the fourth quarter of 2026. Orders on that schedule would support the international leg of the strategy. A miss would add to the pressure from this quarter's revenue drop.
The company also plans to reach 12 sales territories by the end of 2026. Two tests come next. Do the new territories bring in more than 12 customer accounts? Do re-orders lift revenue back above the second-quarter level?
More from OptimistFi
- MBOT stock: research and coverage of Microbot Medical
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
Sources
- Microbot Medical press release, Exhibit 99.1 to Form 8-K — Nov. 16, 2026 release highlighting third-quarter results, cash, customer accounts and the Israel distribution agreement.
- Microbot Medical Form 8-K — Item 7.01 Regulation FD disclosure furnishing the press release.
Explore OptimistFi research on Microbot Medical Inc.: https://optimistfi.com/stocks/MBOT
Browse Microbot Medical Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Microbot Medical Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
